VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MDXG
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MDXGMiMedx Group, Inc.
$3.18$464M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. MDXG
  4. Financial Ratios

MiMedx Group, Inc. (MDXG) Financial Ratios

Latest Ratios: P/E Ratio -24.2x · EV/EBITDA N/A · ROE 21.6%. (2006–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

MDXG Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$464M$1.0B$1.4B$1.3B$314M$667M$983M$811M$189M$1.5B$998M
Enterprise Value$320M$870M$1.4B$1.2B$300M$633M$939M$811M$144M$1.4B$964M
P/E Ratio →-24.1621.1634.3623.08—————22.522531.43
P/S Ratio1.532.424.113.981.172.753.962.710.534.564.07
P/B Ratio1.863.957.438.974.217.2010.7523.573.8119.847.50
P/FCF22.7613.8922.2351.64————7.1725.3356.57
P/OCF6.2613.7021.6647.81————5.2823.2641.85

P/E links to full P/E history page with 30-year chart

MDXG EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—2.083.883.881.122.613.782.710.404.473.93
EV / EBITDA—11.0520.8730.74————48.1727.64151.67
EV / EBIT5.0112.7922.8333.60————13.5030.70278.76
EV / FCF—11.9220.9950.27————5.4624.8654.62

MDXG Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin82.6%82.6%82.8%83.0%82.0%83.6%84.2%85.6%89.9%89.0%86.8%
Operating Margin15.3%15.3%16.9%11.5%-5.5%-2.9%-18.3%-7.1%-1.1%14.4%0.4%
Net Profit Margin11.6%11.6%12.2%21.0%-11.3%-5.1%-19.9%-8.5%-8.3%20.2%4.9%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE21.6%21.6%25.3%62.1%-36.1%-13.4%-78.3%-60.9%-48.6%62.6%9.9%
ROA16.0%16.0%16.9%32.9%-16.8%-6.3%-26.7%-17.6%-24.6%41.2%7.3%
ROIC42.3%42.3%39.7%32.8%-18.4%-10.0%-82.5%-79.7%-11.5%47.7%0.7%
ROCE25.7%25.7%28.6%23.1%-10.8%-4.9%-37.4%-28.0%-6.2%42.4%0.7%

MDXG Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.090.090.130.340.700.580.572.030.000.000.00
Debt / EBITDA0.290.290.381.19————0.080.010.00
Net Debt / Equity—-0.56-0.41-0.24-0.18-0.36-0.480.02-0.90-0.37-0.26
Net Debt / EBITDA-1.82-1.82-1.23-0.84————-15.00-0.52-5.41
Debt / FCF—-1.97-1.23-1.37————-1.70-0.47-1.95
Interest Coverage38.1638.1658.965.74-2.94-1.42-5.59-4.40—538.0810.20

Net cash position: cash ($166M) exceeds total debt ($23M)

MDXG Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio4.324.324.213.573.083.512.711.831.031.062.49
Quick Ratio3.923.923.693.112.783.242.541.700.810.862.14
Cash Ratio2.582.582.291.781.512.061.621.030.630.600.68
Asset Turnover—1.221.321.341.561.291.231.792.922.651.27
Inventory Turnover2.882.882.522.603.673.483.804.732.283.721.82
Days Sales Outstanding—66.0158.4161.1658.7160.8652.0939.430.460.75100.04

MDXG Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield—4.7%2.9%4.3%—————4.4%0.0%
FCF Yield4.4%7.2%4.5%1.9%————14.0%3.9%1.8%
Buyback Yield0.7%0.3%0.2%0.7%0.4%0.7%0.2%0.2%6.6%4.9%1.2%
Total Shareholder Yield0.7%0.3%0.2%0.7%0.4%0.7%0.2%0.2%6.6%4.9%1.2%
Shares Outstanding—$150M$149M$146M$113M$110M$108M$107M$106M$116M$113M

Key Metrics

Growth RegimeContracting
ProfitabilityWeak
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Revenue reversal and reimbursement exposure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Negative Earnings Leave Multiples Uninformative

Based on MDXG's reported figures, the trailing P/E of -25.23 is not meaningful, leaving P/S of 1.59 and P/FCF of 23.77 as the more usable anchors for a company posting losses and volatile free cash flow.

With earnings negative, the P/E cannot be interpreted against history or peers, and forward P/E and EV/EBITDA are unavailable in the supplied data, so valuation rests on sales and cash flow multiples. The P/FCF of 23.77 appears reasonable only if the recent 8.3% free cash flow margin proves durable, which the volatile 2026 path does not yet confirm. Investors should monitor whether a sustained return to positive operating cash flow supports the current multiple.

Gross Margin Holds While Operating Margin Collapses

Reported gross margin of 79.8% in 2026Q3 remains near the 81% to 84% range of 2025, yet operating margin fell from 19.5% in 2025Q3 to a negative 18.8% in the latest quarter, according to reported quarterly figures.

The stable gross margin suggests the product economics of the EpiFix franchise remain intact, which points the deterioration toward operating cost absorption rather than pricing. SG&A of roughly $58M to $60M per quarter against a revenue base that nearly halved implies substantial operating leverage working in reverse. The pattern suggests the earnings base is highly sensitive to volume, warranting caution in extrapolating any single quarter.

Returns Swing From Compounding to Erosion

As reported in financial statements, MDXG's ROIC moved from 14.4% in 2025Q3 to negative 15.2% in 2026Q2 and negative 10.2% in 2026Q3, a reversal that tracks the margin collapse rather than capital intensity.

Return on capital decayed quickly because the capital base stayed substantial while earnings turned negative, so the driver appears to be margins rather than asset efficiency. ROE of negative 4.1% and ROA of negative 3.2% in the latest quarter indicate the equity and asset base are not currently generating returns. The durability of the prior 2025 returns is therefore the central question for assessing whether the business compounds again.

Working Capital Lengthens Cash Conversion Cycle

Based on MDXG's reported figures, the cash conversion cycle expanded from 122 days in 2025Q4 to 142 days in 2026Q3, driven primarily by DIO rising from 125 to 157 days while DSO held near 58 to 62 days.

The lengthening inventory days, combined with DPO that compressed from 63 to 74 days in the wrong direction for the cycle, suggests inventory is building faster than sales are recovering. Asset turnover fell to 0.23 from 0.36, indicating the asset base is no longer generating revenue efficiently. Investors should monitor whether inventory write-down risk emerges if the revenue recovery does not materialize.

Liquidity Remains Strong Despite Cash Decline

Reported current ratio of 4.35 and quick ratio of 3.84 in 2026Q3, against a current ratio of 4.32 in 2025Q4, indicate MDXG retains a considerable short-term buffer even as cash fell from $166.1M to $120.8M.

The near-identical quick and current ratios imply that liquid assets, mainly cash and receivables, dominate current assets, so inventory dependence is limited. Under a severe stress scenario, the reported cash balance alone would appear to cover current liabilities several times over. The more relevant question is the pace of cash burn if operating losses persist at the 2026 run rate.

Medicare Reimbursement Could Compress Net Pricing

Based on MDXG's reported figures, the 2026 revenue decline and margin compression may reflect reimbursement exposure rather than a temporary timing effect, though the supplied data cannot confirm the cause.

The most commonly misapplied metric for this business is gross margin, since a stable 79.8% headline figure can mask net ASP erosion from payer policy changes that do not yet appear in cost of goods. Measuring net revenue per unit and site-of-service mix would better isolate pricing pressure than the headline gross margin. Investors should monitor Medicare administrative contractor rulemaking on skin substitute applications before concluding that the 2026 volume reversal is structural.

Download Financial Ratios Data

Includes 30+ ratios · 20 years · Updated daily

Consensus & Technical Research Suite
Open MDXG Terminal

MDXG Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

MDXG — Frequently Asked Questions

Quick answers to the most common questions about buying MDXG stock.

What is MiMedx Group, Inc.'s P/E ratio?

MiMedx Group, Inc.'s current P/E ratio is -24.2x. The historical average is 27.4x.

What is MiMedx Group, Inc.'s ROE?

MiMedx Group, Inc.'s return on equity (ROE) is 21.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -41.0%.

Is MDXG stock overvalued?

Based on historical data, MiMedx Group, Inc. is trading at a P/E of -24.2x. Compare with industry peers and growth rates for a complete picture.

What are MiMedx Group, Inc.'s profit margins?

MiMedx Group, Inc. has 82.6% gross margin and 15.3% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does MiMedx Group, Inc. have?

MiMedx Group, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.